IPQ Inside the global regulatory dialogue

Industry is Exploring How to Empower Pharmacovigilance Programs to Find GMP Root Causes

Dec 17th, 2013

Please Log in to print the full article

Building a system capable of finding quality problems through a firm’s pharmacovigilance program must begin early in development, one of the leading experts in the field, Lilly Global Patient Safety Senior Director John Ayres, is...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications